Author:
S. Niranjana E.,R. Sambath Kumar,M. Sudha,N. Venkateswaramurthy
Abstract
The world is running out of antibiotics. Between 1940 and 1962, more than 20 new classes of antibiotics were marketed. Since then, only two new classes of antibiotics were marketed. Now, not enough analogues are reaching the market to stem the tide of antibiotic resistance, particularly among gram-negative bacteria which indicates the need of novel antibiotics for their effective action. This review describes those antibiotics in late-stage clinical development. Most of them belong to existing antibiotic classes and a few with a narrow spectrum of activity are novel compounds directed against novel targets. The reasons for some of the past failures to find new molecules and a path forward to help attract investments to fund the discovery of new antibiotics are described.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference31 articles.
1. White AR. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother 2011;66:1948-53.
2. Infectious Diseases Society of America. Bad drugs, No Drugs. Alexandria, Virginia. Infectious Diseases Society of America; 2004.
3. Sabiha I, Twinkle G, Aarti A, Nilanjan D. A comparative study of an antimicrobial profile having broad-spectrum bacteriocins against antibiotics. Asian J Pharm Clin Res 2017;10:44-7.
4. Antibiotics research: problems and perspectives Statement. Academy of Sciences and Humanities in Hamburg German National Academy of Sciences Leopoldina; 2013.
5. Hellen G, Molly MP, Suraj P, Sumanth G, Jordan L, Devra B, et al. State of the World’s Antibiotics: CDDEP; 2015.